VISIBLE
Supports United Kingdom studies on coronary microvascular disease in women and translation into clinical care.
⚠ This may reflect a past cycle — verify the current call on the funder's site.
VISIBLE is a $55 million program co-funded by Wellcome Leap, Pivotal Ventures, and the British Heart Foundation that targets coronary microvascular disease (CMD) in women — a condition currently diagnosed and effectively treated in fewer than 1% of affected patients. The program's stated goal is to increase the proportion of women receiving effective CMD diagnosis and treatment from under 1% to more than 80%. Program Director Dr. Birgit Vogel, a cardiologist specializing in women's cardiovascular health, leads the initiative, which applies Wellcome Leap's outcome-driven, compressed-timeline model to a problem that has been systematically underfunded in cardiovascular research.
The 2026 solicitation accepted full proposal submissions through April 23, 2026 at 11:59 pm ET, with funding decisions communicated on May 23, 2026. Selected performers represent academic institutions, health organizations, and private companies across the United States, United Kingdom, Netherlands, Tanzania, and Australia, reflecting the program's global eligibility. No country restrictions were stated in the solicitation; eligible organization types follow Wellcome Leap's standard performer model covering universities, research institutions, for-profit and nonprofit organizations. The 2026 application cycle is now closed and performers are under contract.
Organizations working on CMD diagnostics, cardiovascular imaging, or women's heart health should monitor Wellcome Leap's website for any future VISIBLE solicitation cycles. The program's performer contract model is milestone-based, as is standard across Wellcome Leap programs, and funded teams operate under multi-year execution agreements. The co-funding structure with Pivotal Ventures and the British Heart Foundation signals sustained institutional commitment to the CMD-in-women problem, making it likely that follow-on solicitation rounds will occur as the program advances.
Diagnosis and treatment of coronary microvascular disease in women, with the goal of increasing the proportion receiving effective care from under 1% to over 80%.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline